Alvarez Mario Moisés, Liu Julie C, Trujillo-de Santiago Grissel, Cha Byung-Hyun, Vishwakarma Ajaykumar, Ghaemmaghami Amir M, Khademhosseini Ali
Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA; Microsystems Technologies Laboratories, Massachusetts Institute of Technology, Cambridge, MA, USA; Centro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, México.
Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA; School of Chemical Engineering and Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
J Control Release. 2016 Oct 28;240:349-363. doi: 10.1016/j.jconrel.2016.01.026. Epub 2016 Jan 14.
Macrophages are key players in many physiological scenarios including tissue homeostasis. In response to injury, typically the balance between macrophage sub-populations shifts from an M1 phenotype (pro-inflammatory) to an M2 phenotype (anti-inflammatory). In tissue engineering scenarios, after implantation of any device, it is desirable to exercise control on this M1-M2 progression and to ensure a timely and smooth transition from the inflammatory to the healing stage. In this review, we briefly introduce the current state of knowledge regarding macrophage function and nomenclature. Next, we discuss the use of controlled release strategies to tune the balance between the M1 and M2 phenotypes in the context of tissue engineering applications. We discuss recent literature related to the release of anti-inflammatory molecules (including nucleic acids) and the sequential release of cytokines to promote a timely M1-M2 shift. In addition, we describe the use of macrophages as controlled release agents upon stimulation by physical and/or mechanical cues provided by scaffolds. Moreover, we discuss current and future applications of "smart" implantable scaffolds capable of controlling the cascade of biochemical events related to healing and vascularization. Finally, we provide our opinion on the current challenges and the future research directions to improve our understanding of the M1-M2 macrophage balance and properly exploit it in tissue engineering and regenerative medicine applications.
巨噬细胞是包括组织稳态在内的许多生理过程中的关键参与者。在受到损伤时,巨噬细胞亚群之间的平衡通常会从M1表型(促炎)转变为M2表型(抗炎)。在组织工程领域,植入任何装置后,希望能够控制这种M1 - M2的进展,并确保从炎症阶段到愈合阶段的及时、平稳过渡。在这篇综述中,我们简要介绍了关于巨噬细胞功能和命名的当前知识状态。接下来,我们讨论在组织工程应用中使用控释策略来调节M1和M2表型之间的平衡。我们讨论了与抗炎分子(包括核酸)释放以及细胞因子的顺序释放以促进及时的M1 - M2转变相关的近期文献。此外,我们描述了巨噬细胞在受到支架提供的物理和/或机械信号刺激后作为控释剂的用途。而且,我们讨论了能够控制与愈合和血管生成相关的一系列生化事件的“智能”可植入支架的当前和未来应用。最后,我们就当前的挑战和未来的研究方向发表意见,以增进我们对M1 - M2巨噬细胞平衡的理解,并在组织工程和再生医学应用中合理利用它。